ResearcherErasmus MCActive in the last 2 years
Leonoor V. Wismans
Matched on ORCID iD 0000-0002-7009-7034; OpenAlex author ID A5055896534. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 27
2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 5
- Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2025.02.002↗
- Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
- Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I stud… Co-author DOI 10.1016/j.ejca.2022.03.015↗
- Robust deep learning model for prognostic stratification of pancreatic ductal adenocarcinoma patients. First author DOI 10.1016/j.isci.2021.103415↗
- Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients? Co-author DOI 10.3390/cancers13122896↗
Closest collaborators
The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Casper H.J. van Eijck · 5 shared papers, 2021–2025 · strength 0.81
- Paper Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer. DOI 10.1016/j.hpb.2025.02.002↗
- Paper Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula… DOI 10.1016/j.surg.2024.01.029↗
- Paper Robust deep learning model for prognostic stratification of pancreatic ductal adenocarcinoma patients. DOI 10.1016/j.isci.2021.103415↗
- Dana A. M. Mustafa · 3 shared papers, 2021–2022 · strength 0.40
- Paper Robust deep learning model for prognostic stratification of pancreatic ductal adenocarcinoma patients. DOI 10.1016/j.isci.2021.103415↗
- Paper Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in… DOI 10.3390/cancers13122896↗
- Paper Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patient… DOI 10.1016/j.ejca.2022.03.015↗
- Casper W.F. van Eijck · 1 shared paper, 2025 · strength 0.26
- Annemiek A. van der Eijk · 1 shared paper, 2025 · strength 0.26
- Willem de Koning · 2 shared papers, 2021–2022 · strength 0.25
- Paper Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in… DOI 10.3390/cancers13122896↗
- Paper Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patient… DOI 10.1016/j.ejca.2022.03.015↗
- Gijs A. Patijn · 1 shared paper, 2024 · strength 0.16
- Izaak Quintus Molenaar · 1 shared paper, 2024 · strength 0.16
- Johanna W. Wilmink · 1 shared paper, 2024 · strength 0.16
- Geertjan van Tienhoven · 1 shared paper, 2024 · strength 0.16
- Vincent Erwin de Meijer · 1 shared paper, 2024 · strength 0.16
- Sebastiaan Festen · 1 shared paper, 2024 · strength 0.16
- Bas Groot Koerkamp · 1 shared paper, 2024 · strength 0.16
- Jelle C. van Dongen · 1 shared paper, 2024 · strength 0.16
- Judith de Vos‐Geelen · 1 shared paper, 2024 · strength 0.16
- José Annelie Suurmeijer · 1 shared paper, 2024 · strength 0.16
- Ignace H. J. T. de Hingh · 1 shared paper, 2024 · strength 0.16
- Bert A. Bonsing · 1 shared paper, 2024 · strength 0.16
- Joost J.M.E. Nuyttens · 1 shared paper, 2024 · strength 0.16
- Hjalmar C. van Santvoort · 1 shared paper, 2024 · strength 0.16
- Marc G. Besselink · 1 shared paper, 2024 · strength 0.16
- Martijn W.J. Stommel · 1 shared paper, 2024 · strength 0.16
- Jie Ju · 1 shared paper, 2021 · strength 0.15
- Yunlei Li · 1 shared paper, 2021 · strength 0.15
- Bernadette G. van den Hoogen · 1 shared paper, 2021 · strength 0.13
- Noel F.C.C. de Miranda · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.